86886-82-0

Basic information

• Product Name: N-(3,4-dichlorophenyl)-4-methylbenzamide
• Synonyms: N-(3,4-dichlorophenyl)-4-methylbenzamide
• CAS NO: 86886-82-0
• Molecular Formula: C₁₄H₁₁Cl₂NO
• Molecular Weight: 280.14924
• Mol File: 86886-82-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3,4-dichlorophenyl)-4-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-dichlorophenyl)-4-methylbenzamide(86886-82-0)
• EPA Substance Registry System: N-(3,4-dichlorophenyl)-4-methylbenzamide(86886-82-0)

Safety Data

• Hazardous Substances Data: 86886-82-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(3,4-dichlorophenyl)-4-methylbenzamide is used as a pharmaceutical intermediate for the synthesis of various drugs and agrochemical products. Its versatile chemical structure allows for the development of new compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
N-(3,4-dichlorophenyl)-4-methylbenzamide is used as a valuable tool in medicinal chemistry for the exploration of its potential biological and pharmacological activities. Its analgesic and antipyretic properties make it a promising candidate for the development of new medications to treat pain and fever.
Used in Drug Development:
N-(3,4-dichlorophenyl)-4-methylbenzamide is utilized in drug development to create new compounds with potential therapeutic benefits. Its unique structure and properties contribute to the advancement of pharmaceutical research and the discovery of innovative treatments for various health conditions.

Upstream product

• 99-54-7 3,4-dichloronitrobenzene 
• 201230-82-2 carbon monoxide 
• 874-60-2 4-methyl-benzoyl chloride 
• 95-76-1 m,p-dichloroaniline 

Downstream Products

• 127351-05-7 N-(3,4-Dichloro-phenyl)-4-methyl-thiobenzamide 

Relevant articles and documents

Design, synthesis and structure-activity relationship of new HSL inhibitors guided by pharmacophore models

Hormone-sensitive lipase (HSL) is a critical enzyme involved in the hormonally regulated release of fatty acids and glycerol from adipocyte lipid stores. Its inhibition may improve insulin sensitivity and blood glucose handling in type 2 diabetes. Accordingly, many small-molecule HSL inhibitors have recently been identified. In continuation of our efforts for discovery of new HSL inhibitors, we prepared a variety of esters, amides, sulfonamides and sulfonate esters capable of fitting two pharmacophore models that we developed and published earlier. The tested compounds were synthesized via coupling reactions of aroyl chlorides or sulfonyl chlorides with phenols, amines and related derivatives. Our efforts led to the identification of interesting compounds of low micromolar anti-HSL bioactivities, which have potential to be developed into effective antidiabetic agents.

Promotion of the [PPN][Rh(CO)4]-catalysed carbonylation of nitrobenzene by 2-hydroxypyridine and related molecules: An apparent bifunctional activation

2-Hydroxypyridine and related molecules have a large activating effect on the previously reported [PPN][Rh(CO)4]-based catalytic system for the reductive carbonylation of nitrobenzene to methyl phenylcarbamate (PPN+=(PPh3)2N+). The effect is not due to the known 2-hydroxypyridine-2-pyridone tautomeric equilibrium, since 4-hydroxypyridine, for which the same tautomeric equilibrium exists, completely inhibits the reaction. A promoting effect of 2-hydroxypyridine is also observed in the reactions of a previously isolated metallacyclic complex, [PPN][Rh(CO)2ON(Ar)C(O)O], believed to be an intermediate in the catalytic reactions. However, the dependence of the rate of the catalytic reactions on the aniline concentration indicates that the effect found for the stoichiometric reaction cannot be the one that is relevant for the acceleration of the catalytic reactions. Thus, two different effects are present, both of which appear to be due to the proximal positions of a basic and an acidic site in the promoter molecules.